Advancing Therapy for Seizures Associated with CDKL-5 Deficiency Disorder
CDKL5 Deficiency Disorder (CDD), an early-onset developmental and epileptic encephalopathy resulting from an abnormality in the cyclin-dependent kinase-like 5 gene which provides instructions for making proteins essential for normal brain and neuron development. Patients with CDD suffer from severe neurodevelopmental delays and early-onset seizures that are often refractory to existing medications. This clinical program will educate decision-makers about the challenges faced by patients with CDD and an option for seizure treatment.
This program will review:
- CDKL5 Deficiency Disorder clinical features including refractory epilepsy.
- Proposed mechanism of a neuroactive steroid.
- CDKL5 Deficiency Disorder-specific clinical trial data in refractory epilepsy.
At the end of the program, attendees should be able to:
- Appreciate the severity of epilepsy in patients with CDKL5 Deficiency Disorder.
- Recognize an antiseizure medication with a differentiated mechanism of action.
- Understand the efficacy and safety data from a CDKL-5 Deficiency Disorder clinical trial.
Speaker:
John A. Flatt, MD
Pediatric Neurologist
Medical Science Liaison - Scientific Affairs
Marinus Pharmaceuticals, Inc.
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
Sponsored by:
For individuals from the media/press who are interested in attending, please email @email.
